Armata Pharmaceuticals Inc. (NYSE American: ARMP) reported positive results from its Phase 2a diSArm study of AP-SA02, a bacteriophage treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE